Stratos Wealth Partners LTD. Sells 319 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Stratos Wealth Partners LTD. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 5,725 shares of the medical research company’s stock after selling 319 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in IQVIA were worth $1,125,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in IQV. Capital Performance Advisors LLP acquired a new stake in IQVIA in the 3rd quarter worth approximately $27,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the fourth quarter worth $33,000. Avior Wealth Management LLC boosted its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the period. Assetmark Inc. grew its stake in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares during the last quarter. Finally, UMB Bank n.a. raised its holdings in IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after acquiring an additional 99 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.9 %

Shares of NYSE IQV opened at $208.13 on Monday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The business has a fifty day moving average of $200.67 and a two-hundred day moving average of $219.40. The stock has a market cap of $37.78 billion, a PE ratio of 27.75, a PEG ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. JPMorgan Chase & Co. dropped their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

Insider Activity at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.